President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日カイル・ディアマンタス <1%
スティーブン・ハーン <1%
ブレット・ジロワール <1%
グレース・グラハム <1%
$39,291 Vol.
$39,291 Vol.
2026/12/30
カイル・ディアマンタス
いいえ
スティーブン・ハーン
いいえ
ブレット・ジロワール
いいえ
グレース・グラハム
いいえ
サラ・ブレナー
いいえ
12月31日までに発表なし
いいえ
カイル・ディアマンタス <1%
スティーブン・ハーン <1%
ブレット・ジロワール <1%
グレース・グラハム <1%
$39,291 Vol.
$39,291 Vol.
2026/12/30
カイル・ディアマンタス
$10,368 Vol.
いいえ
スティーブン・ハーン
$5,255 Vol.
いいえ
ブレット・ジロワール
$5,265 Vol.
いいえ
グレース・グラハム
$6,713 Vol.
いいえ
サラ・ブレナー
$8,024 Vol.
いいえ
12月31日までに発表なし
$3,664 Vol.
いいえ
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
マーケット開始日： May 12, 2026, 7:59 PM ET
音量
$39,291終了日
2026/12/31マーケット開始日
May 12, 2026, 7:59 PM ETリゾルバー
0x69c47De9D...提案された結果: いいえ
異議申し立てなし
最終結果: いいえ
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
音量
$39,291終了日
2026/12/31マーケット開始日
May 12, 2026, 7:59 PM ETリゾルバー
0x69c47De9D...提案された結果: いいえ
異議申し立てなし
最終結果: いいえ
President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問